+ 1 888 391 5441

Investigation Report on China's Ambroxol Market, 2018-2022

Synopsis

Description

The incidence and case fatality rate of respiratory diseases in China are high in recent years. Following cardiovascular and cerebrovascular diseases and cancers, respiratory diseases rank third among the chronic diseases that cause deaths in China. Therefore, developing drugs for the treatment of respiratory diseases has become an important part of drug research. In the case of respiratory infections (respiratory diseases such as chronic bronchitis), a large amount of sputum is produced, which requires the application of expectorants. Respiratory mucus regulators are the main expectorants.

After years of development, third-generation expectorant Ambroxol has become the most common drug in the clinical treatment of respiratory diseases. The chemical constituent of Ambroxol is ambroxol hydrochloride, an active metabolite of Bromhexine. In 1981, Ambroxol (trade name: Mucosolvan) developed by German company Boehringer Ingelheim was launched. Compared with the first and second generations of expectorants, Ambroxol excels in dissolving mucus. In 1994, Boehringer Ingelheim's Ambroxol entered China. Afterwards, the generic drugs by Chinese companies also came onto the market.

This market research, Ambroxol has been growing rapidly since it entered China. From 2005 to 2014, its annual sales value increased from less than CNY 200 million to CNY 1.26 billion, representing a CAGR of 20.9%. From 2015 to 2017, the sales revenue of Ambroxol declined in China. By sales value, Boehringer Ingelheim takes up a market share of about 44%. The rest market share is captured by Chinese companies, among which the top market players are Changzhou Siyao Pharmaceuticals Co., Ltd., Shenyang Xinma Pharmaceutical Co., Ltd., TIPR Pharmaceutical Responsible Co., Ltd. and Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd. Ambroxol is sold in China in the dosage forms of injections, solutions, syrups, granules, tablets and capsules. Injections dominate the market.

As environmental pollution and population aging intensify, the incidence of respiratory diseases will keep rising, it is expected that Ambroxol will still have some growth potential in China in the next few years.

Topics Covered:

  • Situation of respiratory diseases in China
  • Size of China's Ambroxol market
  • Competitive landscape of China's Ambroxol market
  • Prices of Ambroxol in China
  • Analysis on factors affecting the development of China's Ambroxol market
  • Prospect of China's Ambroxol market from 2018 to 2022
Why http://www.chinamarketresearchreports.com

Investigation Report on China's Ambroxol Market, 2018-2022

Price

Related reports :

We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy